MESO Q3 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-35.2% YoY

Gross Profit

-$10M-762.3% margin

Operating Income

-$22M-1750.7% margin

Net Income

-$28M-2204.3% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-25.8%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

-$41,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$669M

Total Liabilities

$189M

Stockholders' Equity

$480M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-35.2%
Gross Profit	-$10M	-$11M	+15.8%
Operating Income	-$22M	-$14M	-52.2%
Net Income	-$28M	-$19M	-49.0%